Peptide library / PT-141

PT-141

PT-141 was the development code for bremelanotide, a cyclic melanocortin peptide. Vyleesi is a specific prescription bremelanotide product.

Peptide & blend guide

The short version

Why people discuss it
Discussed for sexual desire and arousal; the Vyleesi indication applies specifically to acquired generalized HSDD in premenopausal women. Community interest does not establish benefit or a suitable treatment.
What it is
PT-141 was the development code for bremelanotide, a cyclic melanocortin peptide. Vyleesi is a specific prescription bremelanotide product.
Biggest caution
Vyleesi evidence and labeling apply to its specific indication, formulation and population; they do not validate unverified PT-141 products or use for sexual-performance enhancement.
Stack context
Related profiles reflect adjacent community topics or biological context. They do not establish combination benefit, compatibility or a validated regimen.

Dose and frequency reference

Reference only — not a recommendation. Amounts describe source-specific community examples, selected study regimens or the named product label. They do not establish safety, effectiveness, product identity, or a suitable dose for any person. Never convert mg, mcg, or IU into syringe “units” without the exact product concentration.

Source agreement describes reported practice, not clinical validation.

Vyleesi subcutaneous injection

Approved label · Product-specific
Amount
1.75 mg
Frequency
As needed; at least 45 minutes before anticipated activity
Duration / phase
As needed; reassess after 8 weeks without improvement

Vyleesi label for acquired generalized HSDD in premenopausal women: no more than one dose in 24 hours; more than eight doses per month is not recommended. Discontinue after eight weeks without improvement. The new daily community protocol conflicts with this label. Reference only; this does not establish safety, effectiveness or individual suitability.

Reference source · reviewed 2026-09-27
Compare reported schedules

Saved source material reviewed 2026-09-27. Multiple pages from one publisher count as one source family; agreement does not establish what most people use. SC means subcutaneous; IM intramuscular; IP intraperitoneal.

Evidence & sources · Community source profile

AxonRep synthesizes community discussion signals from its internal research corpus. Individual creator sources remain attributed to the synthesis; public reference sites used in the latest comparison are linked separately. The synthesis is not clinical evidence.

Back to the peptide library